Turkish Journal of Gastroenterology
Original Article

FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer


Department of Medical Oncology, Van Regional Training and Research Hospital, Van, Turkey


Department of Internal Diseases, Medical Oncology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey

Turk J Gastroenterol 2014; 25: 198-204
DOI: 10.5152/tjg.2014.3609
Read: 435 Downloads: 71 Published: 25 July 2019


Background/Aims: We aimed to investigate the efficacy and tolerability of a FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer (mCRC) patients.


Materials and Methods: Patients were evaluated in two groups. Group A did not receive any treatment before, and group B had metastasectomy or metastasectomy plus primary tumor resection.


Results: In total, 132 mCRC patients had received FOLFOX7 regimen. The A group consisted of 117 (88.6%) patients, and group B consisted of 15 (11.4%) patients. In the A group, 52.1% had an objective response, 9.4% complete response, 42.7% partial response, 24.8% stable response, and 23.1% progression, and there was a 54.5% rate of primary tumor resection, 22.2% rate of metastasectomy, 80.7% rate of R0 metastasectomy, 19.1% rate of R1 metastasectomy, 15 (10-19) months median progression-free survival, and 32 (22-41) months median overall survival. In the B group, 40 (4-70) months median disease-free survival and 58 (21-94) months median overall survival were found. When toxicities were evaluated, grade 3/4 toxicity was observed in 35.6%. Grade 3/4 hematologic toxicity was the most frequently observed toxicity (29.5%).



Conclusion: FOLFOX7 regimen was found to be an efficient and safe regimen for the first-line treatment of mCRC patients.

EISSN 2148-5607